CClinicalTrials.gg
Sign In
CompletedNCT06661616CONHECTUpdated Oct 28, 2024

Cognitive Effects Associated With Hippocampal Neurogenesis Induced by ECT in the Treatment of Depression

An observational study in Major Depressive Disorder (MDD) and Bipolar Disorder Depression, sponsored by Centre Hospitalier St Anne. Completed at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-28.

Sponsored by Centre Hospitalier St Anne · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
87
Ages
18 Years and older
Sex
All
01

Study summary

Electroconvulsive therapy (ECT) is the treatment of choice for drug-resistant depression (30% of patients), or when there is a short-term risk to the patient's life. Despite its robust efficacy and rapid onset of action, its use is limited both by the limited range of treatment available and by the cognitive effects sometimes induced. The present study focuses on the links between the efficacy of ECT, its cognitive effects and the formation of new neurons in the hippocampus (hippocampal neurogenesis) associated with this treatment.

02

Conditions studied

  • Major Depressive Disorder (MDD)
  • Bipolar Disorder Depression
03

In context

Depression

8,057 studies on the registry are indexed under Depression; 1,641 are open to participants now.

This study's enrollment of 87 is below the median of 160 across 1,084 observational studies indexed under Depression.

Browse Depression studies →

Lead sponsor

Centre Hospitalier St Anne is the lead sponsor of 99 studies on the registry; 53 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

This study focuses on a population of adult patients suffering from unipolar or bipolar depression and treated with electroconvulsive therapy.

In order to monitor the impact of depression on cognitive functions, including memory, and on biological markers and brain imaging, 35 depressed subjects treated without ECT will be recruited.

And to monitor the effect of time on memory, 35 healthy volunteers will be recruited.

Inclusion criteria

  1. Study population: depressed subjects treated with ECT

    • Male or female over 18 years of age
    • Hospitalised at the Centre Hospitalier Sainte-Anne
    • Suffering from a unipolar or bipolar major depressive episode, according to DSM5 criteria
    • Indication for ECT treatment
    • Patient has given informed written consent
    • Beneficiary of a social security scheme

  2. Control population: depressed subjects treated without ECT

    • Male or female over 18 years of age
    • Hospitalised at the Centre Hospitalier Sainte-Anne
    • Suffering from a unipolar or bipolar major depressive episode, according to DSM5 criteria
    • Patient who has given informed written consent
    • Beneficiary of a social security scheme

  3. Control population: healthy volunteers

    • Male or female over 18 years of age
    • Patient with written informed consent
    • Beneficiary of a social security scheme

Exclusion criteria

Exclusion Criteria:

  1. Study population: depressed subjects with ECT

    • Psychiatric comorbidity: schizophrenia, pervasive developmental disorder, dependence on a substance other than tobacco
    • Neurological comorbidity: Parkinson's disease, dementia
    • ECT treatment in the 6 months prior to inclusion
    • Compulsory care
    • Protected adults, persons under court protection measures
    • Persons deprived of liberty by judicial or administrative decision;
    • Refusal of consent to ECT treatment
    • Contraindications to ECT (HTIC, recent history of stroke, severe uncontrolled arterial hypertension, contraindication to anaesthesia)
    • Contraindications to MRI (patients with metal prostheses, claustrophobia)
    • Pregnant or breast-feeding women

  2. Control population: depressed subjects without ECT

    • Psychiatric comorbidity: schizophrenia, pervasive developmental disorder, dependence on any substance other than tobacco
    • Neurological comorbidity: Parkinson's disease, dementia
    • ECT treatment in the 6 months prior to inclusion
    • Compulsory care
    • Protected adults, persons under court protection measures
    • Persons deprived of liberty by judicial or administrative decision;
    • Pregnant or breast-feeding women

  3. Control population: healthyvolunteers

    • Protected adults, persons under legal protection,
    • Persons deprived of their liberty by judicial or administrative decision ;
    • persons hospitalised for purposes other than research
    • Clear psychiatric history
    • Dependence on any substance other than tobacco
    • Neurological history: Parkinson's disease, dementia
    • Pregnant or breast-feeding women
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
87 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Depressed patient treated with electroconvulsivotherapy

    The indication for ECT treatment is established by the department's medical team. Participants are not assigned to ECT as part of this observational study.

  • Depressed patient treated without electroconvulsivotherapy

    The indication for antidepressant treatment is established by the department's medical team. Participants are not assigned to ECT as part of this observational study.

  • Healthy volunteers

    Age- and sex-matched healthy volunteers free of psychiatric disorders.

06

What researchers measure

Primary outcomes

  1. Correlation between increased hippocampal volume and post-ECT retrograde amnesia

    Time frame: After a course of ECT, up to 3 months

07

Study locations

1 site
  • Sainte-Anne Hospital (GHU Paris Psychiatrie et Neurosciences)
    Paris, 75014, France
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06661616
Lead sponsor
Centre Hospitalier St Anne
Responsible party
Sponsor
First posted
Oct 28, 2024
Start date
Jun 6, 2018
Primary completion
May 14, 2024
Completion
May 14, 2024
Last update
Oct 28, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Depression→

Other studies from this sponsor

Centre Hospitalier St Anne

Start the discussion